Loading
A phase 1/2 trial of Tafasitamab, Lenalidomide in diffuse large b-cell lymphoma, run by Incyte Corporation, active and no longer recruiting.
Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients is a phase 1/2 interventional study registered as NCT05222555 by Incyte Corporation, with 53 participants enrolled, started 2022-07-19 and due to reach its primary completion in 2024-07-17. Interventions recorded: Tafasitamab, Lenalidomide. Conditions listed: Diffuse Large B Cell Lymphoma. Results were posted on ClinicalTrials.gov in 2025; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
53 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2025-07-28), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE)primary | Tafasitamab Dose Level 1 + 25 mg Lenalidomide | 6 | 6 participants | - | - | link |
| Tafasitamab Dose Level 2 + 25 mg Lenalidomide | 47 | 45 participants |
Shares Tafasitamab, Incyte, Lenalidomide, PROTACs & molecular glues (targeted protein degradation).
Shares Tafasitamab, Incyte, Lenalidomide, PROTACs & molecular glues (targeted protein degradation).
Shares Tafasitamab, Incyte, Lenalidomide, Monoclonal antibodies.
Shares Tafasitamab, Incyte, Monoclonal antibodies.
Shares Tafasitamab, Incyte, Lenalidomide, PROTACs & molecular glues (targeted protein degradation).
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Monoclonal antibodies.
Shares Tafasitamab, Lenalidomide, Monoclonal antibodies, Diffuse large B-cell lymphoma.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation).